Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > January 7, 2020
Daily News
January 7, 2020
- As Off-Year Re-Pricing Looms, JPMA Chief Prods Govt to Minimize Product Coverage
January 7, 2020
- Leading IBD Care Hospital Switches to Infliximab Biosimilars; Will Others Follow Suit?
January 7, 2020
- Kyorin Grabs Japan Rights to aTyr’s Immunomodulator
January 7, 2020
- Taiho, Astex in KRAS Licensing Deal with US Merck
January 7, 2020
- Kyowa Kirin’s Parkinson’s Med Accepted for Review in Europe
January 7, 2020
- Eisai’s Fycompa Now Available in China
January 7, 2020
- Ono, Seikagaku File Novel Osteoarthritis Treatment in Japan
January 7, 2020
- Sumitomo Dainippon Closes US$3 Billion Roivant Deal
January 7, 2020
- Urovant, Now under Sumitomo Dainippon, Seeks US Approval for Vibegron
January 7, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…